Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Phase 1/2 initial data of Duvelisib - CONTEMPO trial for treatment-naive patients with follicular lymphoma due 2H 2016 -Study Withdrawn

Source Link:: http://phx.corporate-ir.net/phoenix.zhtml?c=121941&p=RssLanding&cat=news&id=2128081

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

INFI

Community voting in process

VSTM

Community voting in process

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details 2016 Duvelisib Goals Infinity expects to achieve the following duvelisib milestones in 2016: Report topline DYNAMO data in 3Q16 Report topline DUO data in 2H16* Submit a New Drug Application (NDA) for iNHL and CLL in 4Q16* AbbVie submission of Marketing Authorization Application (MAA) for follicular lymphoma and CLL in 4Q16* Report initial data from CONTEMPO, a Phase1b/2 study in treatment-naïve patients with follicular lymphoma, in 2H16 Advance Phase 1b/2 study of duvelisib in combination with venetoclax

http://phx.corporate...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Jun 29, 2016

Occurred Source:

https://clinicaltrials.gov/archive/NCT02576275/2016_06_29/changes

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1/2 Initial Data, Duvelisib, Conetempo Trial, Treatment-naive Patients, Follicular Lymphoma, 2h 2016